News 
Market Data 
Discover
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
|
Followers
|
0
|
Posters
|
|
|
Posts (Today)
|
0
|
Posts (Total)
|
10
|
|
Created
|
10/30/05
|
Type
|
Free
|
| Moderators | |||
MPMA .016 x .019
Next GLIF runner?
Here's a post from September from I-HUB...bounced off
first part of private placement:
http://www.investorshub.com/boards/read_msg.asp?message_id=7861054&txt2find=mpma+
Why the fall?
A 2.75M share private placement in which a portion still
needed to be completed(from the 10Q report):
In April 2005, the Company commenced a private placement of 2,750,000 shares of
unregistered common stock at a purchase price of $0.10 per share. As of August
17, 2005, an aggregate of 1,600,000 shares had been sold to twenty- five (25)
accredited investors for aggregate net proceeds to the Company of $160,000. In
addition, as of August 22, 2005, the Company obtained short-term working capital
financing aggregating $55,000.
Comment:
A private placement temporarily dilutes a stock to raise money
for a particular cause...similar to an S-8, SB-2, S-1, preferred
converting to common, etc. Most penny stocks raise money this
way. Fortune 500 companies do private placements at times, too.
What the company is currently doing(from the 10Q):
Pursuant to two Sponsored Research Agreements between the Company and Weill
Medical College of Cornell University ("WMC") and a License Agreement, as
amended, with Cornell Research Foundation, Inc., a subsidiary of Cornell
University ("Cornell"), the Company has been granted the exclusive license to
develop and market a medical compound which has certain derivatives that are
directed towards
(i) the treatment of cancer as a highly water-soluble agent having low
toxicity towards non-cancerous cells,
(ii) potentially, the treatment of cancer as a site directed
chemotherapeutic agent that selectively attacks only cancer cells
through a specific delivery device depending on the site- directing
agent, and
(iii) the treatment of HIV/AIDS as an anti-HIV activity
which could be used either systemically as an AIDS therapy or locally
as a bopcidal compounds for the inhibition of the sexual acquisition
of HIV.
Recent P.R.'s:
Marc Pharmaceuticals Betulinol Drug Candidate Slows Prostate Tumor Growth in Laboratory Mice
Friday September 23, 10:00 am ET
STAMFORD, Conn.--(BUSINESS WIRE)--Sept. 23, 2005--University scientists working under a research program sponsored by Marc Pharmaceuticals, Inc. (OTC:MPMA - News; OTC:MPMAW - News; OTC:MPMAZ - News), recently completed a 17-day study on laboratory animals. The study results showed that one of Marc's water soluble drug candidates (a Betulinol derivative) slowed prostate tumor growth in mice. Betulinol is a naturally occurring compound that is isolated from the outer layer of the bark of the white birch tree. Betulinol derivatives are formed by replacing a specific atom or group of atoms within a betulinol molecule.
Link to rest of the P.R.:
http://biz.yahoo.com/bw/050923/235161.html?.v=1
Marc Pharmaceuticals Announces Positive Pre-Clinical HIV Results
Thursday August 4, 11:00 am ET
Will Begin Early Stage Studies of Betulinol Derivatives on Drug Resistant HIV
STAMFORD, Conn.--(BUSINESS WIRE)--Aug. 4, 2005--Preliminary experimental data from cellular tests conducted by university scientists working under a research grant sponsored by Marc Pharmaceuticals, Inc. (OTC:MPMA - News; OTC:MPMAW - News; OTC:MPMAZ - News) has demonstrated that a betulinol derivative inhibits HIV-1 replication by more than 90 percent with no evidence of detrimental changes to cell viability. These encouraging early stage results pave the way for further pre-clinical studies in drug resistant strains of HIV.
Link to rest of the P.R.:
http://biz.yahoo.com/bw/050804/45231.html?.v=1
Website:
http://www.marcpharmaceuticals.com/
Volume:
Volume has been particulary high the last few trading days which
means they sold the remaining shares at the lowest point they
could which gives the company cheaper financing(FANC, the MM, dumped
1M shares on two different lots on Friday). That contributed
to a 1/3 of Friday's volume. Most traders don't know the scoop
here...they haven't done the due diligence. This just started to
get recognized late Friday.
Chart:
A bottombuster similar to GLIF when it hit bottom. DD both
charts(GLIF's and MPMA's)
O/S:
State the number of shares outstanding of each of the issuer's classes of common
equity, as of the latest practicable date: As of August 22, 2005, the issuer had
outstanding (i) 288,160,000 shares of Common Stock, par value $. 0001 per share.
Final comment:
Bottombuster material: 3-5 bagger potential or more.
